Search clinical trials for: Corifollitropin alfa 150μg

Total 3286 results

Catalyst Biosciences

Completed

Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia

Hemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without Inhibitor

Bulgaria, Russian Federation
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency

Spain, Germany, Italy, United States, Croatia, Canada, Russian Federation, Denmark, United Kingdom, Belgium, Mexico, Australia, Netherlands, Brazil, Turkey
Genzyme, a Sanofi Company

Terminated

A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease

Glycogenosis 2 | Glycogen Storage Disease Type II (GSD II) | Acid Maltase Deficiency | Pompe Disease (Infantile-Onset)

United States, Taiwan, Germany
Novo Nordisk A/S

Terminated

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding (CONTROL)

Trauma | Acquired Bleeding Disorder

Spain, Hong Kong, Germany, France, United Kingdom, Brazil, Italy, Hungary, Netherlands, United States, Switzerland, Czech Republic, Greece, South Africa
University of New Mexico
University of Utah

Completed

Mild Encephalopathy in the Newborn Treated With Darbepoetin (MEND)

Hypoxic-Ischemic Encephalopathy Mild | Neonatal Encephalopathy

United States
Azidus Brasil
Blau Farmaceutica S.A.

Completed

Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.

Renal Insufficiency, Chronic

Brazil
Swedish Orphan Biovitrum

Completed

A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B (PREVENT)

Haemophilia A | Haemophilia B

Germany
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease

Acquired Immunodeficiency Syndrome | Anemia
Organon and Co

Completed

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783) (Care)

Pregnancy | Neonates
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer

Head and Neck Cancer | Anemia

United States, Canada, Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery

Hemostasis, Surgical
Biocad

Completed

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

Reticulocyte Count
Sanofi

Completed

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

Hemophilia A

Bulgaria
Columbia University
Merck Sharp & Dohme LLC

Withdrawn

Boceprevir in End Stage Renal Disease (ESRD)

End Stage Renal Disease | Hepatitis C Infection
Boston Children's Hospital
Brigham and Women's Hospital; South Shore Hospital

Recruiting

Pulmozyme to Improve COVID-19 ARDS Outcomes

COVID

United States
Genzyme, a Sanofi Company

Completed

Pompe Lactation Sub-Registry

Glycogen Storage Disease | Pompe Disease

United States
Alexion Pharmaceuticals, Inc.
Xcenda, LLC

Active, not recruiting

Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)

Hypophosphatasia

United States
Swedish Orphan Biovitrum
Cerner Enviza

Active, not recruiting

An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B (B-MORE)

Hemophilia B

Czechia, Greece, Ireland, Italy, Norway, Saudi Arabia, Spain, Sweden, United Kingdom
Swedish Orphan Biovitrum
Cerner Enviza

Completed

A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France (B-SURE)

Haemophilia B

France
AIO-Studien-gGmbH
Merck Serono GmbH, Germany

Terminated

Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer (NEOBIL)

Cholangiocarcinoma | Biliary Tract Cancer

Germany
National Cancer Institute (NCI)

Terminated

A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

Urothelial Cancer

United States
AryoGen Pharmed Co.

Completed

Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency

Factor VII Deficiency

Iran, Islamic Republic of
PharmaEssentia Japan K.K.
PharmaEssentia

Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

Australia
Genentech, Inc.

Terminated

A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis

Cystic Fibrosis
Genzyme, a Sanofi Company

Terminated

A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease

Pompe Disease

United States
University of Colorado, Denver
Genentech, Inc.

Completed

Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)

Otitis Media

United States
Novo Nordisk A/S

Completed

Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers

Healthy | Congenital Bleeding Disorder

Japan
National Institute of Neurological Disorders and...

Completed

An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease

Fabry Disease

United States
National Institute of Neurological Disorders and...

Completed

Replagal Enzyme Replacement Therapy for Adults With Fabry Disease

Fabry Disease

United States
Sanofi
Pulse Infoframe Ltd.

Recruiting

A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

Niemann-Pick Diseases | Acid Sphingomyelinase Deficiency

United States
Fondation Ophtalmologique Adolphe de Rothschild

Recruiting

Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target) (NETs-target)

Ischemic Stroke

France
JCR Pharmaceuticals Co., Ltd.

Active, not recruiting

An Extension Study of JR-171-101 Study in Patients With MPS I

Mucopolysaccharidosis I

United States, Brazil, Japan
Genzyme, a Sanofi Company

Completed

Avalglucosidase Alfa Extension Study (NEO-EXT)

Glycogen Storage Disease Type II Pompe Disease

United States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
Chiesi Farmaceutici S.p.A.

Active, not recruiting

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

Fabry Disease

United States, Netherlands, Australia, Hungary, United Kingdom, Canada, Czechia, Finland, France, Italy, Norway, Slovenia, Spain
Genentech, Inc.

Terminated

A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)

Cystic Fibrosis

United States
Genentech, Inc.

Completed

A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
Genzyme, a Sanofi Company

Completed

Late-Onset Treatment Study Extension Protocol

Glycogen Storage Disease Type II (GSD-II) | Pompe Disease (Late-Onset) | Glycogenesis Type II | Acid Maltase Deficiency (AMD)

United States, France, Canada, Netherlands, Australia
Hallym University Medical Center

Recruiting

High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia

Anemia

Korea, Republic of
Bayer

Completed

Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (DIALOGUE4)

Renal Insufficiency, Chronic | Anemia

United States, Japan
Genzyme, a Sanofi Company

Active, not recruiting

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

Thyroid Cancer

United States, Italy, Poland, Russian Federation, United Kingdom, Netherlands, Israel, Czechia, India
Indiana University
Eli Lilly and Company

Terminated

The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia (Beta)

Schizophrenia

United States
Henry M. Jackson Foundation for the Advancement...
Gilead Sciences

Withdrawn

Antiretroviral Therapy for Acute HIV Infection

HIV Infections

Uganda
Region Stockholm

Not yet recruiting

The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy (FOXTROT)

Diabetes Complications | Diabetes; Nephropathy (Manifestation)

Sweden
Bayer

Completed

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (DIALOGUE5)

Renal Insufficiency, Chronic | Anemia

United States, Japan
Gilead Sciences

Completed

Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

Chronic Hepatitis Delta

France, Moldova, Republic of, Romania, Russian Federation
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Von Willebrand Disease (VWD)

United States, Italy, Spain, Netherlands, Turkey, France, Austria, Germany, Russian Federation
Chiesi Farmaceutici S.p.A.

Terminated

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

Acute Respiratory Distress Syndrome

United States, Italy, United Kingdom
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma

Multiple Myeloma | Anemia | Plasma Cell Neoplasm

United States
Sandoz

Terminated

Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients

Anemia | Chronic Renal Insufficiency

Austria, Slovakia, Russian Federation, Romania, Poland, Czechia, France, Germany, India, Bulgaria
Amgen

Completed

Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia

Anemia | Congestive Heart Failure

Search clinical trials for: Corifollitropin alfa 150μg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations